Understanding how a protein called ANGPTL3 affects cholesterol and fat levels in the liver
Project 2: ANGPTL3-dependent mechanisms underlying adaptations in hepatic lipoprotein production and clearance
This research explores how blocking a protein called ANGPTL3 helps the liver manage cholesterol and fats, which could lead to new ways to prevent heart disease and diabetes.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11096557 on NIH RePORTER |
What this research studies
Our bodies produce fats and cholesterol, and the liver plays a key role in managing these levels. This project looks at how a specific protein, ANGPTL3, influences how the liver makes and clears these substances. We are studying how reducing ANGPTL3 might lower 'bad' cholesterol (LDL) and other fats that can harm your heart. By understanding these processes, we hope to uncover new ways to keep your heart and blood vessels healthy.
Who could benefit from this research
Good fit: This foundational research is for individuals interested in the underlying causes of high cholesterol, high triglycerides, heart disease, and adult-onset diabetes.
Not a fit: Patients not affected by high cholesterol, high triglycerides, or related cardiovascular and metabolic conditions may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new medications or strategies to lower harmful cholesterol and triglyceride levels, potentially preventing or managing heart disease and adult-onset diabetes.
How similar studies have performed: Inhibiting ANGPTL3 has recently shown promise as a new treatment approach for reducing both LDL cholesterol and triglyceride-rich lipoproteins in other studies.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Stitziel, Nathan Oliver — University of Washington
- Study coordinator: Stitziel, Nathan Oliver
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.